MRNA - TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron But Timidly

• After a long and painful downside, TFFP's stock has finally delivered a one-day outperformance with respect to the big Covid plays due to the Omicron variant.
• The next question is whether this is just another blip as was the case in July when there were positive clinical trials results for Augmenta's drug candidate using TFF (Thin Film Freezing) delivery.
• The answer lies in the ability to leverage existing drugs with known safety profiles and reformulate these such as Niclosamide.
• Despite high operational expenses, finances are adequate, with the pharma sharing costs through partnerships with biotechs.
• Still, at an early stage, the road to commercialization could be a long one, but in the meanwhile, there are opportunities to benefit through licensing of intellectual property assets.

For further details see: